Savara Inc (NASDAQ:SVRA) Receives $10.17 Average PT from Brokerages

Savara Inc (NASDAQ:SVRA) has been given an average rating of “Moderate Buy” by the six brokerages that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $10.17.

SVRA has been the topic of a number of recent research reports. HC Wainwright cut their target price on Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. JMP Securities restated a “market outperform” rating and set a $9.00 price objective on shares of Savara in a research note on Tuesday, October 1st. Finally, Evercore ISI reiterated an “in-line” rating and issued a $5.00 target price (down previously from $7.00) on shares of Savara in a research note on Wednesday, November 13th.

Savara Trading Down 4.3 %

NASDAQ SVRA opened at $3.56 on Friday. Savara has a 52 week low of $2.82 and a 52 week high of $5.70. The business has a 50 day moving average price of $3.56 and a 200-day moving average price of $4.04. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13. The company has a market cap of $610.96 million, a price-to-earnings ratio of -8.28 and a beta of 0.92.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, hitting the consensus estimate of ($0.11). As a group, equities analysts expect that Savara will post -0.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Savara

In related news, Director Joseph S. Mccracken bought 20,000 shares of the company’s stock in a transaction on Tuesday, November 19th. The shares were purchased at an average cost of $2.95 per share, for a total transaction of $59,000.00. Following the completion of the purchase, the director now directly owns 210,837 shares in the company, valued at $621,969.15. The trade was a 10.48 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 5.13% of the company’s stock.

Institutional Investors Weigh In On Savara

Hedge funds have recently modified their holdings of the stock. Choreo LLC purchased a new stake in Savara in the second quarter worth $59,000. DRW Securities LLC purchased a new stake in Savara in the 2nd quarter worth about $62,000. Virtu Financial LLC purchased a new stake in Savara in the 3rd quarter worth about $67,000. Principal Financial Group Inc. raised its stake in Savara by 64.4% in the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after acquiring an additional 6,973 shares during the period. Finally, Profund Advisors LLC purchased a new stake in Savara during the second quarter valued at about $105,000. Institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.